We are live on ! Find out more
KBIO

KaloBios Pharmaceuticals
KBIO

Delisted

KBIO was delisted on the 16th of December, 2015.

1 hedge funds and large institutions have $65K invested in KaloBios Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% less funds holding

Funds holding: 17 → 1 (-16)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $4.19M

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 16

Holders
1
Holders Change
-16
Holders Change %
-94.12%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KBIO Hedge Fund Activity: Q1 2016 in Review

1 of the 3,768 institutional investors tracked by Wall St. Rank reported a position in KaloBios Pharmaceuticals (KBIO) for Q1 2016, worth a combined $65K — down 99% from $4.45M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of KBIO and 0 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $2.61M sold.

  • 1 institutional investor held KaloBios Pharmaceuticals (KBIO) as of Q1 2016, down from 17 in Q4 2015.
  • Funds reported $65K of KaloBios Pharmaceuticals stock for Q1 2016, down 99% quarter-over-quarter.
  • 0 funds opened new KaloBios Pharmaceuticals positions in Q1 2016 and 16 closed out, a net change of -16 holders.
  • The largest KaloBios Pharmaceuticals seller in Q1 2016 was Renaissance Technologies, an estimated $2.61M sold.

Based on aggregated 13F filings for Q1 2016.